Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis.
Eur J Pharmacol. 2024 Mar 5;966:176366. doi: 10.1016/j.ejphar.2024.176366. Epub 2024 Feb 1.
Eur J Pharmacol. 2024.
PMID: 38296153
N-butyldeoxynojirimycin (miglustat) ameliorates pulmonary fibrosis through inhibition of nuclear translocation of Smad2/3.
Nakamura H, Zhou Y, Sakamoto Y, Yamazaki A, Kurumiya E, Yamazaki R, Hayashi K, Kasuya Y, Watanabe K, Kasahara J, Takabatake M, Tatsumi K, Yoshino I, Honda T, Murayama T.
Nakamura H, et al. Among authors: kurumiya e.
Biomed Pharmacother. 2023 Apr;160:114405. doi: 10.1016/j.biopha.2023.114405. Epub 2023 Feb 15.
Biomed Pharmacother. 2023.
PMID: 36804125
Free article.
Item in Clipboard
Cite
Cite